Jones Financial Companies Lllp raised its holdings in Schrodinger, Inc. (NASDAQ:SDGR - Free Report) by 34,925.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 216,110 shares of the company's stock after acquiring an additional 215,493 shares during the period. Jones Financial Companies Lllp owned 0.30% of Schrodinger worth $4,266,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Two Sigma Advisers LP acquired a new position in Schrodinger in the 4th quarter valued at $473,000. Allspring Global Investments Holdings LLC raised its holdings in Schrodinger by 30.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 174,371 shares of the company's stock valued at $3,442,000 after acquiring an additional 40,568 shares during the last quarter. GAMMA Investing LLC raised its holdings in Schrodinger by 118.5% in the 1st quarter. GAMMA Investing LLC now owns 6,109 shares of the company's stock valued at $121,000 after acquiring an additional 3,313 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Schrodinger during the 4th quarter valued at $330,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Schrodinger during the 4th quarter valued at $1,939,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Schrodinger Trading Down 1.5%
NASDAQ:SDGR traded down $0.29 on Monday, reaching $18.29. The stock had a trading volume of 193,262 shares, compared to its average volume of 1,143,978. The company has a 50-day moving average of $20.22 and a 200 day moving average of $21.62. The stock has a market cap of $1.35 billion, a P/E ratio of -7.37 and a beta of 1.79. Schrodinger, Inc. has a 12-month low of $16.60 and a 12-month high of $28.47.
Schrodinger (NASDAQ:SDGR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.59) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.24. The company had revenue of $54.76 million during the quarter, compared to analysts' expectations of $52.03 million. Schrodinger had a negative net margin of 76.22% and a negative return on equity of 45.70%. The firm's revenue for the quarter was up 15.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.66) EPS. On average, equities analysts predict that Schrodinger, Inc. will post -2.37 EPS for the current year.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on SDGR. Wall Street Zen cut shares of Schrodinger from a "hold" rating to a "sell" rating in a research note on Saturday, August 30th. KeyCorp lowered their price objective on shares of Schrodinger from $32.00 to $30.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. Morgan Stanley lowered their price objective on shares of Schrodinger from $28.00 to $19.00 and set an "equal weight" rating for the company in a research note on Monday, August 18th. Barclays began coverage on shares of Schrodinger in a research note on Thursday, August 14th. They set an "overweight" rating and a $25.00 price objective for the company. Finally, Citigroup cut shares of Schrodinger from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $35.00 to $20.00 in a research note on Friday, August 15th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $27.83.
Check Out Our Latest Report on Schrodinger
Schrodinger Company Profile
(
Free Report)
Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
Further Reading

Before you consider Schrodinger, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Schrodinger wasn't on the list.
While Schrodinger currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.